Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540157 | 0.84 | MTNR1A (0.49) | MTNR1AMTNR1BFFAR1LMNAPLA2G10 | |
| SCHEMBL1541346 | 0.83 | MAPT (0.50) | MAPTMTNR1AMTNR1BSMN1; SMN2HPGD | |
| SCHEMBL1540823 | 0.76 | MTNR1A (0.41) | MTNR1AMTNR1BFFAR1KDM4EPLA2G10 | |
| SCHEMBL1540331 | 0.76 | RAB9A (0.55) | MTNR1AMTNR1BSMN1; SMN2HPGDFFAR1 | |
| SCHEMBL1540191 | 0.75 | FFAR1 (0.48) | MAPTMTNR1AMTNR1BFFAR1RAB9A | |
| SCHEMBL1540560 | 0.75 | MTNR1A (0.45) | MAPTMTNR1AMTNR1BSMN1; SMN2FFAR1 | |
| SCHEMBL1539946 | 0.74 | RAB9A (0.59) | SMN1; SMN2HPGDLMNARAB9ANPC1 | |
| SCHEMBL1540430 | 0.72 | MTNR1A (0.47) | MAPTMTNR1AMTNR1BSMN1; SMN2FFAR1 | |
| SCHEMBL29047082 | 0.72 | MAPT (0.71) | MAPTHPGDLMNAKDM1ANPC1 | |
| SCHEMBL6024362 | 0.69 | MAOA (0.53) | MAPTMTNR1AMTNR1BSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | MAPT 4640/4885MTNR1A 3683/4885MTNR1B 3250/4885 |
| US-20100240715-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAPT 4100/4885MTNR1A 2095/4885MTNR1B 2319/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | MAPT 4463/4885MTNR1A 1666/4885MTNR1B 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.